Compare Gold Fields Limited (GFI) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gold Fields Limited vs Novartis AG — how do they compare? Gold Fields Limited trades at $41.18 (market cap $36.07B), while Novartis AG trades at $152.7 (market cap $295.37B). The key difference: Novartis AG is far larger — about 8.2× Gold Fields Limited's market cap, and Gold Fields Limited pays the higher dividend (5.76%). Which is the better fit depends on your goals.
| GFI | NVS | |
|---|---|---|
Market Cap | $36.07B | $295.37B |
Sector | Basic Materials | Health |
52-Week High | $61.52 | $168.62 |
52-Week Low | $29.31 | $119.31 |
Enterprise Value | $37.51B | $336.69B |
Dividend Yield | 5.76% | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gold Fields Limited (GFI) trades at $41.12, up 0.73% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong profitability with a 40.76% net income margin and ROE of 52.33%, though recent quarterly earnings missed expectations. Revenue grew to $5.2B in 2024, with net income reaching $1.25B. Analyst consensus is a Buy with a $52 price target, indicating 26% upside potential.
The outlook for GFI is positive given its robust fundamentals and gold price tailwinds, but risks include volatile earnings performance and rising debt levels. Institutional accumulation and favorable sector sentiment support the bullish case, though investors should monitor cost pressures and execution on growth targets.
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
